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INTmmUKIN-6 (IL-6) is a multifunctional cytokine that
regulates the immune response, acute phase anaphylactic
reaction, and haematopoiesis. Lipopolysaccharide
(6-24tg/ml) significantly induced IL-6 release from
murine spleen cells. In cultured rabbit synovial cells
interleukin-1 (IL-1, 1-10 U/ml) induced IL-6 production
in a concentration-dependent manner. Triazolodiazepine
(Tri) is a hetrazepine platelet-activating factor antagonist.
In this study we found that Tri (0.1-10 limol/D exerted
strong inhibitory effects on LPS stimulated IL-6 produc-
tion in murine spleen cells. Kinetic studies showed that
the inhibition of IL-6 release was time-independent. In
rabbit synovial cells Tri also reduced IL-6 release induced
by IL-1 and tumour necrosis factor. Inhibition ofcytokine
production by Tri may partially explain its wide and
strong anti-inflammatory effects.
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Introduction
Interleukin-6 (IL-6) is a multifunctional cytokine
that regulates the immune response, acute phase
anaphylactic reaction, and haematopoiesis. It is
known that IL-6 is produced by various cells. Con-
sidering that IL-6 production may play a critical role
in a number of disease, chronic inflammation, and
lymphoid malignancies, relatively little is known
about the effects of anti-inflammatory drugs on
cytokine synthesis. It might therefore be worthwhile
investigating the relationship between its inhibition
and the mechanism of action of anti-inflammatory
drugs. Triazolodiazepine (Tri) is a hetrazepine plate-
let-activating factor (PAF) antagonist. It exerts strong
anti-inflammatory effects on many in vivo and in
vitro models. In the present study, the effects of Tri
on the production of IL-6 from mouse splenocytes
and cultured rabbit synovial cells were examined.
Materials and Methods
Animals and chemicals: ICR mice weighing 16-24 g
and New Zealand rabbits weighing 1.5-2.5 kg were
purchased from the Zoological Experiment Center
of the Second Military Medical University. RPMI-
1640, MEM media and lipopolysaccharide (LPS,
Escherichia coli, 055:B5) were purchased from Sigma
Chemical Co., USA. Foetal calf serum (FCS) was sup-
plied by the Department of Pathology, Second Mili-
tary Medical University. Triazolodiazepine (Tri, WEB
2086) was a kind gift from Boehringer Ingelheim Co.,
Germany. PH]-TdR (814 TBq/mol) was obtained from
Shanghai Institute of Nuclear Research, Chinese
Academy of Sciences. Recombinant human tumour
necrosis factor (TNF) was generously provided by Dr
Y. Sohmura, Dainippon Pharmaceutical Co., Japan.
Spleen cell preparation and IL-6 induction:
Splenocytes were prepared from spleens removed
under sterile conditions from sacrificed ICR mice.
The cells were suspended in RPMI-1640 containing
penicillin 100 U/ml, streptomycin 100 btg/ml, 2-
mercaptoethanol 50 mmol/1 and 10% FCS. The cells
were cultured in sterile 24-well tissue culture plates
(Corning, USA) at a density of 5 x 106 cells/ml/well
with LPS alone or in combination with different
concentrations of Tri. After 48 h incubation at 37C
in a 5% CO2, humidified atmosphere, the
supernatants were collected by centrifugation and
stored-20C until testing for IL-6 activity.
IL-6productionfrom rabbit synovial cells in culture:
Rabbit synovial cells were cultured according to Ju.
Briefly, synovial membrane tissue was obtained
aseptically from the knees of normal adult New
Zealand rabbits. The membrane was cut into pieces
and stuck to a culture flask with the inner side
towards the flask wall. MEM medium supplemented
with 10% FCS, penicillin (100 U/mol) and streptomy-
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cin (100 btg/ml) were added to the flask and cultiva-
tion was carried out at 37C. When the cells had
grown to confluence, they were trypsinized and
seeded into a 24-well plate. Twenty-four hours later,
the compounds to be tested were added to the cell
monolayer. After 24 h incubation the supernatants
were collected by centrifugation and stored at-20C
for IL-6 assay.
IL-6 bioassay: To measure IL-6 activity in the
supernatants, the murine IL-6 dependent hybridoma
cell line 7TD1 was used. Briefly, cells were cultured
on culture flasks in RPMI-1640 with 10% FCS and
recombinant human IL-6 (gifts from Dr Steven Gillis,
Immunex Co., USA). 7TD1 cells were seeded into 96-
well fiat-bottomed microtitre plates (Nunclon, Den-
mark) at a density of 1000 cells/well. Supernatants to
be tested were added to the cells and incubated for
3 days in a humidified atmosphere. Cells were pulsed
with PH]-TdR 18500 Bq for the last 12 h and were
collected using a cell harvester. The incorporation of
PH]-TdR was measured using a FJ-2107 scintillation
counter (Xi-an, China).
Results
IL-6production induced by LP& The levels of IL-6
production were determined by measuring the radio-
activity of PH]-TdR incorporation in 7TD1 cells. LPS
at 6-12 t.tg/ml markedly induced IL-6 production
from murine spleen cells (Fig. 1).
Inhibition ofTri on IL-6productionfrom splenocytes:
Splenocytes were incubated with LPS and Tri for
48 h. The release of IL-6 induced by LPS (12 lttg/ml)
was shown to be significantly reduced by Tri at
0.1-10 btmol/1 in a concentration-dependent manner
as indicated in Fig. 2.
Time course ofIL-6production: Tri co-cultured with
LPS stimulated splenocytes for 24, 36, 48, 60 and
72 h. The data in Fig. 3 shows that at all times tested,
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FIG. 1. Effect of lipopolysaccaride (LPS) on the production of interleukin-6
(IL-6) in mouse splenocytes, x S.D., n= 6, p< 0.05, **p < 0.01 vs
control.
5000
4000
3000
2000
1000
1
0.0!, 0.1 10
WEB 2086 concentration (lmol/L)
FIG. 2. Inhibitory effects of triazolodiazepine (Tri) on LPS (12 lgtml) stimu-
lated IL-6 production in murine splenocytes, x S.D., n 6, *p < 0.01 vs
control.
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FIG. 3. Time-independent inhibition of Tri (10 mol/I) on the production of
IL-6 in mouse splenocytes, x S.D., n 6, *p < 0.05, **p < 0.01 vs LPS
group.., LPS alone; [], LPS+WEB 2086.
Tri (10 btmol) elicited strong inhibitory effects on IL-
6 production in murine spleen cells, suggesting that
Tri inhibited IL-6 production in a time-independent
manner.
IL-6production from synovial cells: Rabbit synovial
cells were stimulated with IL-1 and TNF for 24 h. The
results demonstrated that IL-1 at 10 and 100 U/ml,
TNF at 1 and 10 U/ml both significantly stimulated IL-
6 release from synovial cells. The inducing effects
seemed to be concentration-dependent (Table 1).
Table 1. Effects of tumour necrosis factor (TNF) and interleukin-1
(IL-1) on IL-6 production from cultured rabbit synovial cells.
x + S.D., n= 6, *p < 0.05, **p < 0.01 vs control
Drugs U/ml IL-6 activity (cpm)
Control 2081 + 328
IL-1
2217 + 256
10 2533 +/- 374*
100 3450 +/- 476**
TNF
0.1 2398 +/- 522
2870 +/- 513**
10 4253 +/- 631
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FIG. 4. Inhibitory effects of Tri on the production of IL-6 induced by IL-1 (100
U/ml) and TNF (10 U/ml) from rabbit synovial cells, x+S.D., n=6,
*p < 0.05, **p < 0.01 vs control.,, IL-1 (100 U/ml); [], TNF (10 U/ml).
Reduction o.f IL-6production from synovial cells by
Tri: IL-6 release challenged by IL-1 (100 U/ml) was
markedly reduced by Tri (10 btmol/1). Tri also inhib-
ited TNF (10 U/ml) induced IL-6 production at 1 and
10 l.tmol/1 (Fig. 4).
Discussion
IL-6 is known to have multiple actions on the
growth, differentiation and function of lymphoid and
non-lymphoid cells. It has recently been suggested
that this cytokine plays a role in the pathogenesis of
autoimmune disorders, in which excessive produc-
tion of IL-6 may lead to abnormal B-cell differentia-
tion and antibody production. This study demon-
strates that LPS significantly induced IL-6 production
from murine spleen cells in vitro. Since splenocyte
culture is a mixture of T-cells, B-cells and
macrophages, the data here do not provide direct
insight into the cellular source of IL-6. It is reported
that macrophages, fibroblasts and endothelial cells
are the main IL-6 producing cells, but we also found
that IL-1 and TNF stimulated IL-6 production in cul-
tured rabbit synovial cells. IL-6 release from synovial
cells in arthritic DBA/ij mice was reported by Sugita
et al. Elevation of IL-6 levels in sera and paws of
autoimmune arthritic animals was also demon-
strated.1 In previous work it was found that IL-6
stimulated proliferation of synovial cells. These data
suggest that abnormal IL-6 production may be an
important pathological parameter and a contributory
factor in the proliferative lesions of arthritic disease.
Tri is a specific PAF antagonist. We found that Tri
reduced the production of TNF from murine
peritoneal macrophages, IL-1 and colony-stimulating
factor from mouse splenocytes.4,n In this study we
found that Tri exerted strong inhibitory effects on IL-
6 production from LPS stimulated murine spleen cells
and cultured rabbit synovial cells. We speculate that
PAF may play an essential role in the production of
these cytokines. PAF is a major inflammatory media-
tor which may interact with other cytokines such as
IL-1, IL-6, CSF and TNF, thereby resulting in an
autocatalytic augmentation of the inflammatory re-
sponse.3’12-14 Tri, being able to exhibit strong inhibi-
tory effects on the production of these mediators,
may be of great use in anti-inflammatory therapy.
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